Sodium Fluoride Dentifrice

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dental Health

Conditions

Dental Health

Trial Timeline

Oct 1, 2009 → Dec 1, 2009

NCT ID

NCT01009554

About Sodium Fluoride Dentifrice

Sodium Fluoride Dentifrice is a pre-clinical stage product being developed by Johnson & Johnson for Dental Health. The current trial status is completed. This product is registered under clinical trial identifier NCT01009554. Target conditions include Dental Health.

What happened to similar drugs?

1 of 8 similar drugs in Dental Health were approved

Approved (1) Terminated (0) Active (7)

✅2 mg nicotine gum + 4 mg nicotine gumJohnson & JohnsonApproved

🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3

🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3

🔄acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3

🔄Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3

🔄Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3

🔄Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01009554	Pre-clinical	Completed	Oct 1, 2009	Dec 1, 2009	Dental Health

Competing Products

20 competing products in Dental Health

See all competitors

Product	Company	Stage	Hype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tablet	Johnson & Johnson	Phase 3	40
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + Placebo	Johnson & Johnson	Phase 3	40
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + Placebo	Johnson & Johnson	Phase 2	35
2 mg nicotine gum + 4 mg nicotine gum	Johnson & Johnson	Approved	43
Acetaminophen ER + Placebo	Johnson & Johnson	Phase 2	35
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsule	Johnson & Johnson	Phase 3	40
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassium	Novartis	Phase 3	40
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	35
Pregabalin + Alprazolam + Placebo	Pfizer	Phase 2	35
Prototype (AN0128 Toothpaste)	Pfizer	Phase 1	29
PF-05089771 + PF-05089771 + PF-05089771 + Ibuprofen	Pfizer	Phase 2	35
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	35
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	27
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo	Bayer	Phase 3	37
XPF-001 + placebo	Xenon Pharmaceuticals	Phase 2	32
N1539 + placebo + N1539 + N1539 + Motrin	Alkermes	Phase 2	32
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placebo	Organon	Phase 3	34
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + Placebo	AFT Pharmaceuticals	Phase 2	17
Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo	AFT Pharmaceuticals	Phase 3	30
C16G2 Gel	Armata Pharmaceuticals	Phase 2	25